Home

Articles from Zealand Pharma

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Company announcement – No. 4 / 2025
By Zealand Pharma · Via GlobeNewswire · March 12, 2025
Zealand Pharma Announces Financial Results for the Full Year 2024
Company announcement – No. 2 / 2025
By Zealand Pharma · Via GlobeNewswire · February 20, 2025
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Press Release – No. 3 / 2025
By Zealand Pharma · Via GlobeNewswire · February 13, 2025
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Press Release – No. 2 / 2025
By Zealand Pharma · Via GlobeNewswire · January 7, 2025
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
Press Release – No. 1 / 2025
By Zealand Pharma · Via GlobeNewswire · January 6, 2025
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
Company announcement – No. 51 / 2024
By Zealand Pharma · Via GlobeNewswire · December 19, 2024
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press Release – No. 12 / 2024
By Zealand Pharma · Via GlobeNewswire · December 10, 2024
Zealand Pharma to participate in the Jefferies London Healthcare Conference
Press Release – No. 11 / 2024
By Zealand Pharma · Via GlobeNewswire · November 13, 2024
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
Company announcement – No. 49 / 2024
By Zealand Pharma · Via GlobeNewswire · November 7, 2024
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Press Release – No. 10 / 2024
By Zealand Pharma · Via GlobeNewswire · November 1, 2024
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
Company announcement – No. 48 / 2024
By Zealand Pharma · Via GlobeNewswire · October 8, 2024
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
Company announcement – No. 47 / 2024
By Zealand Pharma · Via GlobeNewswire · October 8, 2024
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
Company announcement – No. 46 / 2024
By Zealand Pharma · Via GlobeNewswire · September 30, 2024
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
Press Release – No. 9 / 2024
By Zealand Pharma · Via GlobeNewswire · September 13, 2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 45 / 2024
By Zealand Pharma · Via GlobeNewswire · September 12, 2024
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 44 / 2024
By Zealand Pharma · Via GlobeNewswire · September 9, 2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 41 / 2024
By Zealand Pharma · Via GlobeNewswire · August 22, 2024
Zealand Pharma Announces Financial Results for the First Half of 2024
Company announcement - No. 39 / 2024
By Zealand Pharma · Via GlobeNewswire · August 15, 2024
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Press Release – No. 8 / 2024
By Zealand Pharma · Via GlobeNewswire · August 12, 2024
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Press release – 7 / 2024
By Zealand Pharma · Via GlobeNewswire · July 29, 2024
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
Company announcement – No. 35 / 2024
By Zealand Pharma · Via GlobeNewswire · June 25, 2024
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
Company announcement – No. 34 / 2024
By Zealand Pharma · Via GlobeNewswire · June 25, 2024
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
Company announcement – No. 33 / 2024
By Zealand Pharma · Via GlobeNewswire · June 25, 2024
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Company announcement – No. 32 / 2024
By Zealand Pharma · Via GlobeNewswire · June 20, 2024
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Company announcement - No. 30 / 2024
By Zealand Pharma · Via GlobeNewswire · June 7, 2024
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
Company announcement - No. 29 / 2024
By Zealand Pharma · Via GlobeNewswire · June 6, 2024
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
Press release – No. 6 / 2024
By Zealand Pharma · Via GlobeNewswire · May 31, 2024
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Press release – No. 5 / 2024
By Zealand Pharma · Via GlobeNewswire · May 29, 2024
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 27 / 2024
By Zealand Pharma · Via GlobeNewswire · May 23, 2024
Zealand Pharma Announces Financial Results for the First Quarter of 2024
Company announcement - No. 26 / 2024
By Zealand Pharma · Via GlobeNewswire · May 16, 2024
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Press Release – No. 4 / 2024
By Zealand Pharma · Via GlobeNewswire · May 9, 2024
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
Press release – No. 3 / 2023
By Zealand Pharma · Via GlobeNewswire · March 1, 2024
Zealand Pharma Announces Financial Results for the Full Year 2023
Company announcement - No. 9 / 2024
By Zealand Pharma · Via GlobeNewswire · February 27, 2024
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Company announcement - No. 8 / 2024
By Zealand Pharma · Via GlobeNewswire · February 26, 2024
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
Press Release – No. 2 / 2024
By Zealand Pharma · Via GlobeNewswire · February 20, 2024
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Company announcement – No. 5 / 2024
By Zealand Pharma · Via GlobeNewswire · January 19, 2024
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Company announcement – No. 4 / 2024
By Zealand Pharma · Via GlobeNewswire · January 17, 2024
Zealand Pharma completes registration of capital increase
Company announcement – No. 3 / 2024
By Zealand Pharma · Via GlobeNewswire · January 12, 2024
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
Company announcement – No. 2 / 2024
By Zealand Pharma · Via GlobeNewswire · January 10, 2024
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
Company announcement – No. 1 / 2024
By Zealand Pharma · Via GlobeNewswire · January 8, 2024
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
Press Release – No. 1 / 2024
By Zealand Pharma · Via GlobeNewswire · January 2, 2024
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
Company announcement – No. 45 / 2023
By Zealand Pharma · Via GlobeNewswire · December 23, 2023
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Press release – No. 18 / 2023
By Zealand Pharma · Via GlobeNewswire · December 22, 2023
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
Press release No. 17 / 2023
By Zealand Pharma · Via GlobeNewswire · December 22, 2023
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
Press release – No. 16 / 2023
By Zealand Pharma · Via GlobeNewswire · December 4, 2023
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
Company announcement – No. 40 / 2023
By Zealand Pharma · Via GlobeNewswire · November 30, 2023
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
Company announcement - No. 38 / 2023
By Zealand Pharma · Via GlobeNewswire · November 9, 2023
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
Press release – No. 15 / 2023
By Zealand Pharma · Via GlobeNewswire · November 7, 2023
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
Press Release – No. 14 / 2023
By Zealand Pharma · Via GlobeNewswire · November 3, 2023
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
Press release – No. 13 / 2023
By Zealand Pharma · Via GlobeNewswire · October 17, 2023
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
By Zealand Pharma · Via GlobeNewswire · October 5, 2023
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
Press release – No. 11 / 2023
By Zealand Pharma · Via GlobeNewswire · September 8, 2023
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
Press release – No. 10 / 2023
By Zealand Pharma · Via GlobeNewswire · September 7, 2023
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
Company announcement – No. 31 / 2023
By Zealand Pharma · Via GlobeNewswire · August 30, 2023
Zealand Pharma Announces Financial Results for the First Half of 2023
Company announcement - No. 28 / 2023
By Zealand Pharma · Via GlobeNewswire · August 17, 2023
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
Press Release – No. 9 / 2023
By Zealand Pharma · Via GlobeNewswire · August 14, 2023
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
Company announcement – No. 27 / 2023
By Zealand Pharma · Via GlobeNewswire · July 3, 2023
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
Press release – No. 8 / 2023
By Zealand Pharma · Via GlobeNewswire · June 30, 2023
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Press release – No. 6 / 2023
By Zealand Pharma · Via GlobeNewswire · June 24, 2023
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Press Release­­­­­­­ No. 5 / 2023
By Zealand Pharma · Via GlobeNewswire · June 23, 2023
Zealand Pharma Announces Financial Results for the First Quarter of 2023
Company announcement - No. 20 / 2023
By Zealand Pharma · Via GlobeNewswire · May 11, 2023
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
By Zealand Pharma · Via GlobeNewswire · May 10, 2023
Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results
Press Release– No. 3 / 2023
By Zealand Pharma · Via GlobeNewswire · May 4, 2023
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
Press release – No. 2 / 2023
By Zealand Pharma · Via GlobeNewswire · April 12, 2023
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
Company announcement – No. 11 / 2023
By Zealand Pharma · Via GlobeNewswire · March 30, 2023
Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares
Company announcement – No. 10 / 2023
By Zealand Pharma · Via GlobeNewswire · March 30, 2023
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Company announcement – No. 7 / 2023
By Zealand Pharma · Via GlobeNewswire · March 28, 2023
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 3 / 2023
By Zealand Pharma · Via GlobeNewswire · March 9, 2023
Correction: Zealand Pharma convenes its Annual General Meeting 2023
Correction: Company Announcement – No. 2 / 2023
By Zealand Pharma · Via GlobeNewswire · March 3, 2023
Correction: Zealand Pharma Announces Full Year Results for 2022
Company announcement – No. 1 / 2023
By Zealand Pharma · Via GlobeNewswire · March 2, 2023
Zealand Pharma convenes its Annual General Meeting 2023
Company Announcement – No. 2 / 2023
By Zealand Pharma · Via GlobeNewswire · March 2, 2023
Zealand Pharma Announces Full Year Results for 2022
Company announcement – No. 1 / 2023
By Zealand Pharma · Via GlobeNewswire · March 2, 2023
Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
Press release – No. 1 / 2023
By Zealand Pharma · Via GlobeNewswire · February 24, 2023
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Company announcement No. 51 / 2022
By Zealand Pharma · Via GlobeNewswire · November 10, 2022
Zealand Pharma to Participate in Upcoming Investor Conferences
Company announcement – No. 50 / 2022
By Zealand Pharma · Via GlobeNewswire · November 8, 2022